Dexcom’s new CEO is eyeing growth in the international market as a key strategy for 2026, fresh off the back of the company reporting strong full year 2025 (FY25) revenues. Speaking at the ongoing J.P. Morgan Healthcare Conference, Dexcom’s new CEO Jake Leach said: “We've built our company based on leadership in the US, and we're now going to take that and apply it to the international markets, particularly our ability to open up access and coverage for people with CGM to unlock new opportunities that don ...